A Phase 2, multicenter, prospective, randomized, double-blind, Minoxidil and vehicle controlled, dose-ranging study to evaluate the efficacy and safety of CB-03-01 (Cortexolone 17α-propionate) solution for the treatment of androgenetic alopecia in females
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Clascoterone (Primary) ; Minoxidil
- Indications Female pattern baldness
- Focus Therapeutic Use
- Sponsors Cassiopea
- 22 Jul 2021 Status changed from recruiting to completed.
- 29 Jul 2020 According to the Cassiopea SpA media release, due to COVID-19, there was an approximately three month interruption in the recruitment of subjects.
- 11 Jun 2020 Status changed from suspended to recruiting.